Hospital Acquired Infections Testing Kits Market Overview 2024-2033 – Competitive Landscape and Strategies

The global Hospital Equipment and Supplies market size is estimated to reach USD 95.00 billion to 2028 from USD 39.54 billion in 2020, delivering a CAGR of 12.3%.

In a bid to avoid transmission of diseases and contamination of hospital supplies, these organizations recommended the adoption of high barrier drapes, gowns, gloves, along with potent disinfectants in ambulatory operating rooms and hospitals.The global spending on healthcare is rising steadily across the globe; It was USD 7.8 trillion in or nearly 10% of GDP in 2017.

Moreover, the recent outbreak of COVID-19 has led organizations to invest heavily in healthcare facility cleanliness and disinfection, which will further supplement hospital equipment and supplies market share over the forecast period.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2963Further key findings from the report suggestOn the basis of product type, the disposable hospital supplies segment held 22.6% of the hospital equipment and supplies market share in 2019 and is estimated to witness exponential growth on account of growing patient awareness regarding hospital-acquired infections and enforcement of infection prevention standards in hospitals across several countries.Based on expenditure type, the public hospitals account for 34.9% of the hospital equipment and supplies market share and is set to witness a growth rate of 12.8% through 2017.

The growth is a result of favorable initiatives taken by the government in developing economies to upscale healthcare facilities.

For instance, the Government in MEA and APAC countries are focusing on the sourcing of advanced medical supplies and equipment for enhancing public hospital infrastructure.Based on distribution channel, the retail medical store segment is estimated to exhibit a CAGR of 12.4% over the analysis period.

Pharmacies are wholesale suppliers to hospitals under a contract to provide optimal quality medical supplies.In the regional landscape, the APAC region is forecast to register a growth rate of 13.5% through 2027.

According to the latest report by IMARC Group titled, “Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024”, the market was worth US$ 876 Million in 2018.

Looking forward, IMARC expects the market to reach a value of US$ 2,190 Million by 2024, growing at a CAGR of around 16.5% during the next five years.Hospital-acquired disease (HAD) testing involves the diagnosis of infections and medical ailments potentially caused by bacterial, viral and fungal pathogens.

These ailments, including gastrointestinal, bloodstream and urinary tract infections (UTIs), are usually acquired from clinics, nursing homes, rehabilitation facilities or hospitals, when the outer layer of the skin comes in contact with pathogens which results in infections, especially after surgical operations.

HAD testing commonly involves molecular diagnostics, urinalysis, immunoassay and physical examination of the infected area.The global market is primarily driven by the increasing prevalence of HADs, especially in developing countries, owing to inadequate hygiene facilities available in the healthcare institutions.

Furthermore, technological advancements and innovations in testing equipment, which facilitate efficient diagnosis, monitoring and prevention of HADs, are also contributing to the increasing adoption of testing devices across the globe.

Other factors, including favorable government policies to improve healthcare infrastructure, along with an increasing number of research and development (R) activities in the healthcare sector, are projected to drive the market further.Request for a sample copy of this report: https://www.imarcgroup.com/hospital-acquired-disease-testing-market/requestsampleHospital Acquired Disease Testing Market Segmentation:Market Breakup by Indication1.

The hospital acquired infections therapeutic market size is expected to reach USD 12.52 billion by 2028 according to a new study by Polaris Market Research.

The report “Hospital Acquired Infections Therapeutic Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial Drugs {Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, Others}, Antiviral Drugs, Antifungal Drugs); By Infection Type; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.Rising tolerance towards antibiotics in lethal pathogens also induced the market demand for novel therapeutics for treating hospital acquired infections.

The majority of players in the market for hospital acquired infections therapeutic are continuously involved in research & development activities to develop new drugs to gain a competitive advantage.In this direction, in June 2019, Food & Drug Administration (FDA) approved Merck’s Zerbaxa (ceftolozane and tazobactam) drug for the treatment of ventilator-associated infections in patients aged 18 years and older.

This is expected to drive the market for hospital acquired infections therapeutic.Over the past few decades, chronic diseases such as diabetes, heart-related ailments, and arthritis are rising at an alarming speed.

As per the data published by International Agency for Research on Cancer (IARC), in 2018, reported around 18.1 million new cancer cases.Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/hospital-acquired-infections-therapeutic-market/request-for-sampleAsia Pacific is expected to register a lucrative market growth rate over the hospital acquired infection therapeutic study period.

This market growth for hospital acquired infection therapeutic is attributed to the rising prevalence of chronic diseases in developing nations with high disposable income, which had led to an increase in hospital admissions.For instance, as per the market study done by Globocan, in 2018, there were 4,285,033 new cancer cases in China.

The HAI diagnostics market size is projected to cross $4.3 billion by 2023, growing at a CAGR of 7.6% between 2017-2023.In terms of application, the HAI diagnostics market is segmented into drug-resistance testing and disease testing.

The drug-resistance testing held the larger share in the market in 2016, owing to the modernization in molecular diagnostics that has enabled drug-resistance testing.

With the development of novel testing techniques such as phenotypic resistance testing, hybridization methods, sample processing and sequencing the diagnosis rate has increased to may folds and is expected to grow in near future.Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/hospital-acquired-infection-diagnostics-market/report-sampleThe European HAI diagnostics market is projected to grow at a steady pace during 2017-2023, to cross $1.2 billion by 2023.

According to the International Trade Administration (ITA), there is growth in the market, with the major companies such as Roche Diagnostics Limited, Abbott Laboratories, and others investing more in the R of the innovative diagnostics products to remain competitive in this field.

Along with it, the growth of the hospital acquired diagnostics market in Europe is also characterized by the increase in geriatric population and high incidence of hospital acquired infections.Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hospital-acquired-infection-diagnostics-marketTechnologically advanced products aid by offering accurate and reliable results with low turnaround time.

Major companies in the HAI diagnostics market are investing in the development of the molecular diagnostics, looking forward to the growth and demand in the field.